Bioelectrix has been selected as one of eight Nordic deep-tech teams in the REACH 2025–26 cohort, a Silicon Valley–based incubator program run by Nordic Innovation House to accelerate the commercialisation of research-driven technologies with global ambition.
Why REACH matters for Bioelectrix
Building breakthrough medtech starts with strong technology but winning in the market requires much more than technical performance.
In wound care, adoption depends on whether a new solution can prove it fits into real clinical workflows, delivers measurable outcomes, and can scale across systems with very different decision makers (clinicians, clinic managers, procurement teams, and in many cases payers). REACH is designed to help teams move through that commercialization phase faster and with less risk by sharpening the value proposition, validating customer needs, and building the network required for partnerships, pilots, and eventual scale in the US. We want to make sure we are aligned with the requirements for approval and adoption in the US, and REACH is the perfect first step to get there.
A six-month program built around execution and mentorship
REACH runs over six months and combines structured workshops with hands-on mentoring and external meetings for customer, partner, and investor validation. In addition, all teams travel to Palo Alto for two weeks in April of 2026 to visit.
We are part of a cohort of eight Nordic deep-tech teams working across healthcare, climate, education, food systems, and industrial efficiency. That mix is a real advantage for us. Working alongside teams solving different problems with the same level of technical depth creates a steep learning curve and practical inspiration — from how others approach validation and product development to how they structure partnerships and go-to-market. At the same time, the program strengthens our network in our own field. Through the cohort, coaches, mentors, and the wider ecosystem around REACH, we are building valuable connections with medtech operators, potential partners, and investors that can help accelerate our path to clinical adoption and scale
A key part of the REACH experience is access to coaches and mentors who have helped multiple Nordic teams navigate the jump from research excellence to commercial execution in the US.Nathan Gold, Tristan Kromer, Arne Tonning, Gro Dyrnes, Anne Wolfson, Armann Kojic, Eva Nahari, Shomit Ghose, Han Jin, Nicolae Paladi, Ellen Andreasson, and Anette Nordvall are some of the coaches we have had the pleasure of talking to.
Our main coach going forward: Negin Mokhtari
As Bioelectrix moves into the next phase of REACH, we are especially excited to work closely with Negin Mokhtari, who will be our main coach going forward.
Negin brings a rare combination of scientific depth and commercialization experience from the US market. She is a scientist by training (PhD in drug and gene delivery) and has experience building and supporting ventures through strategy, business development, and investment roles.
What we are focusing on next
With the online phase complete and mentoring continuing, we now shift into execution mode ahead of the Silicon Valley immersion in spring 2026.
Our focus in this next phase includes:
- deeper customer discovery and validation conversations,
- sharpening our value proposition for the stakeholders who decide adoption,
- and building relationships that can accelerate partnerships, pilots, and market entry in the US.
Thank you
We are grateful to Nordic Innovation House and the broader REACH ecosystem of mentors, alumni, and partners for welcoming Bioelectrix into the 2025–26 cohort.
